Ebola Virus Disease is one of the most dangerous diseases, which has the whole world holding its breath as it watches the disastrous effects unfold in the south of Africa. As the casualties mount up, the scientists and medical personnel around the world scramble about to bring peace this region and come up with treatments and vaccines to counter the current outbreak.
The scientists at the Vaccine Research Centre (VRC), which is a part of the National Institute of Allergy and Infectious Disease (NIAID), have had more success at developing a for the Ebola vaccine. The Ebola vaccine was developed in a partnership with the GlaxoSmithKline (GSK).
The clinical trials were conducted on 20 people who were given the vaccine are aged between 18 to 50 years and are currently showing immunity to the virus. The Ebola vaccine contains two strains of the virus, the Zaire and the Sudan, inserted into an adenovirus 3. The adenovirus 3 or cAD 3 commonly affects chimpanzees and does not cause disease in humans. The vaccine showed the anticipated reaction and produced antibodies against the Ebola virus within 4 weeks of administrating the vaccine.
Julie Ledgerwood is a researcher at the NIAID Vaccine Research Center and the lead investigator of the trial said, “We know from previous studies in non-human primates that CD8 T cells played a crucial role in protecting animals that had been vaccinated with this NIAID/GSK vaccine and then exposed to otherwise lethal amounts of Ebola virus. The size and quality of the CD8 T cell response we saw in this trial are similar to that observed in non-human primates vaccinated with the candidate vaccine.”
The vaccine caused the immune system to respond to the bits of Ebola virus and resulted in the generation of CD8 T cells which help the immune system to fight off infections like this.
“The unprecedented scale of the current Ebola outbreak in West Africa has intensified efforts to develop safe and effective vaccines, which may play a role in bringing this epidemic to an end and undoubtedly will be critically important in preventing future large outbreaks. Based on these positive results from the first human trial of this candidate vaccine, we are continuing our accelerated plan for larger trials to determine if the vaccine is efficacious in preventing Ebola infection.” said the director of NIAID, Dr. Anthony Fauci.